BAXTER INTERNATIONAL INC false 0000010456 --12-31 0000010456 2022-05-03 2022-05-03 0000010456 bax:CommonStock1.00PerValueMember 2022-05-03 2022-05-03 0000010456 bax:M0Member 2022-05-03 2022-05-03 0000010456 bax:GlobalNotes13Due2025Member 2022-05-03 2022-05-03 0000010456 bax:GlobalNotes13Due2029Member 2022-05-03 2022-05-03 0000010456 bax:GlobalNotes04Due2024Member 2022-05-03 2022-05-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2022

 

 

Baxter International Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   1-4448   36-0781620

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

One Baxter Parkway, Deerfield, Illinois   60015
(Address of principal executive offices)   (Zip Code)

(224) 948-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $1.00 par value   BAX (NYSE)   New York Stock Exchange
    Chicago Stock Exchange
1.3% Global Notes due 2025   BAX 25   New York Stock Exchange
1.3% Global Notes due 2029   BAX 29   New York Stock Exchange
0.4% Global Notes due 2024   BAX 24   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

  Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(e) of the Exchange Act  ☐

 

 

 


Item 3.03

Material Modification to Rights of Security Holders.

The information set forth in Item 5.03 of this Current Report on Form 8-K (this “Current Report”) is incorporated herein by reference.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment and Compensation of D. Brent Shafer and Peter M. Wilver as Directors.

On May 3, 2022, Baxter International Inc. (the “Company”) appointed each of D. Brent Shafer and Peter M. Wilver to its Board of Directors (the “Board”), with such appointments to become effective on May 10, 2022. Upon their appointment to the Board on May 10, 2022, the number of directors constituting the Board will increase to thirteen directors. Upon their appointment to the Board, Mr. Shafer will be appointed to serve on the Audit Committee and Compensation Committee and Mr. Wilver will be appointed to serve on the Compensation Committee.

Mr. Shafer, 64, previously served as the Chairman of the Board and Chief Executive Officer of Cerner Corporation from 2018 to 2021. Prior to Cerner, Mr. Shafer held a number of roles at Koninklijke Philips NV, including Chief Executive Officer of Philips North America and Chief Executive Officer of Philips Home Healthcare Solutions business. Before joining Philips, Mr. Shafer was vice president and general manager of Hillrom’s Patient Care Environment Division and worked at GE Medical Systems where he served in key positions in sales, marketing, and general management. Mr. Shafer has also held senior roles at Hewlett Packard’s Medical Products Group and Johnson & Johnson. He currently serves as a director of Tactile Systems Technology.

Mr. Wilver, 62, previously served as the Executive Vice President and Chief Administrative Officer of Thermo Fisher Scientific, Inc. from 2015 until his retirement in 2017. Mr. Wilver also served as Thermo Fisher’s chief financial officer, a position he held from 2004 to 2015. Prior to Thermo Fisher, Mr. Wilver was the chief financial officer for Honeywell’s Electronic Materials Division. Before joining Honeywell, he held various finance roles at Grimes Aerospace Company and General Electric Company. Mr. Wilver currently serves as a director of Shoals Technologies Group Inc. and Evoqua Water Technologies Corporation.

Mr. Shafer and Mr. Wilver will each be compensated for his service as a director pursuant to the Company’s Non-Employee Director Compensation Plan filed as Exhibit 10.26 to the Company’s Annual Report on Form 10-K filed on February 23, 2022 (the “2022 Form 10-K”), and will be eligible to participate in the Company’s Directors’ Deferred Compensation Plan filed as Exhibit 10.18 to the Company’s 2022 Form 10-K. In connection with joining the Board, Mr. Shafer and Wilver will each be granted equity awards as compensation for a portion of their 2022 service (representing the period between May 10, 2022 and the 2023 Annual Meeting) in an amount consistent with the awards granted annually to non-employee directors, prorated for the full calendar months to be served during such period in accordance with the terms of the Company’s Non-Employee Director Compensation Plan. A description of the Company’s non-employee director compensation arrangements can be found in the section titled “Proposal 1. Election of Directors-Director Compensation” in the Company’s definitive proxy statement for its 2022 Annual Meeting filed on March 21, 2022 (and amended on March 28, 2022) and is incorporated herein by reference.

Retirement of Mr. Peter S. Hellman.

On May 4, 2022, Peter S. Hellman notified the Company of his decision to retire from the Board, effective as of June 30, 2022. Following Mr. Hellman’s retirement on June 30, 2022, the number of directors constituting the Board will decrease to twelve directors.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On May 3, 2022, the Company held its annual meeting of stockholders (the “2022 Annual Meeting”) at which the stockholders approved the following two amendments to the Company’s Amended and Restated Certificate of Incorporation (as further described under Item 5.07 of this Current Report):

 

   

An amendment to add a new Article ELEVENTH to permit stockholder action by written consent following a request by record holders who have beneficially owned shares representing a “net long position” of at least 25% of the Company’s common stock entitled to vote on the matter for at least one year so long as such action is approved by holders of shares representing not less than the minimum number of shares required to take such action at an annual or special meeting, subject to the satisfaction of certain procedural safeguards set forth therein (the “Written Consent Charter Amendment”). A stockholder’s “net long position” is generally defined as those shares of common stock as to which a


 

stockholder possesses both (i) the full voting and investment rights pertaining to the shares and (ii) the full economic interest in (including the opportunity for profit from and risk of loss on) such shares; provided, that Net Long Beneficial Ownership does not include any shares as to which such person does not have the right to vote or direct the vote, or as to which such person has entered into a derivative or other agreement, arrangement or understanding that hedges or transfers, in whole or in part, directly or indirectly, any of the economic consequences of ownership of such shares.

 

   

An amendment to Article TWELFTH to change the stock ownership threshold required for stockholders to request a special meeting from record holders of at least 25% of the Company’s outstanding common stock entitled to vote on the matter(s) to be brought before the proposed special meeting to record holders who have beneficially owned shares representing a “net long position” of at least 15% of the outstanding shares of Common Stock entitled to vote on the matter(s) to be brought before the proposed special meeting for at least one year (the “Special Meeting Charter Amendment” and, together with the Written Consent Charter Amendment, the “Charter Amendments”)

On May 5, 2022, the Company filed its Amended and Restated Charter (the “Amended and Restated Charter”), reflecting the Charter Amendments, with the Secretary of State of the State of Delaware, with such Amended and Restated Charter becoming effective immediately upon filing.

On February 15, 2022, in connection with the Charter Amendments, the Board approved a corresponding amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”) to reflect the new special meeting ownership threshold, with such Amended and Restated Bylaws becoming effective immediately upon the filing of the Amended and Restated Charter.

The foregoing description of the Amended and Restated Charter and Amended and Restated Bylaws is qualified in its entirety by reference to the text of the Amended and Restated Charter and Amended and Restated Bylaws, copies of which are attached hereto as Exhibits 3.1 and 3.2, respectively, and are incorporated herein by reference.

 

Item 5.07

Submission of Matters to a Vote of Security Holders

On May 3, 2022, the Company held its 2022 Annual Meeting in a virtual format. Of the 503,197,000 shares outstanding and entitled to vote, 447,845,077 shares were represented at the meeting, constituting a quorum of approximately 89%. The following is a summary of the matters voted on at the 2022 Annual Meeting.

 

(a)

The eleven nominees for director were elected as follows:

 

Nominee    For      Against      Abstain      Broker Non-Votes  

José (Joe) E. Almeida

     384,473,820        27,138,213        2,192,265        34,040,779  

Thomas F. Chen

     397,665,546        9,870,623        6,268,129        34,040,779  

Peter S. Hellman

     389,880,292        23,572,504        351,502        34,040,779  

Michael F. Mahoney

     401,357,935        12,096,939        349,424        34,040,779  

Patricia B. Morrison

     410,121,031        3,368,893        314,374        34,040,779  

Stephen N. Oesterle

     405,592,708        7,856,986        354,604        34,040,779  

Nancy M. Schlichting

     399,354,971        14,134,459        314,868        34,040,779  

Cathy R. Smith

     407,895,932        5,599,580        308,786        34,040,779  

Albert P.L. Stroucken

     386,615,470        26,844,274        344,554        34,040,779  

Amy A. Wendell

     406,527,028        6,962,497        314,773        34,040,779  

David S. Wilkes

     411,552,025        1,901,999        350,274        34,040,779  

 

(b)

By the following vote, stockholders approved, on an advisory basis, the 2021 compensation paid to the Company’s named executive officers:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

375,423,883   37,478,137   902,278   34,040,779

 

(c)

The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2022 was ratified by the following vote:

 

For

 

Against

 

Abstain

417,865,402   29,622,889   356,786

 

(d)

By the following vote, stockholders approved the Written Consent Charter Amendment to permit stockholder action by written consent (as described in Item 5.03 of this Current Report):

 

For

 

Against

 

Abstain

 

Broker Non-Votes

409,319,021   3,979,369   505,908   34,040,779


(e)

By the following vote, stockholders approved the Special Meeting Charter Amendment to lower the special meeting threshold (as described in Item 5.03 of this Current Report):

 

For

 

Against

 

Abstain

 

Broker Non-Votes

404,787,410   7,212,995   1,803,893   34,040,779

 

(f)

By the following vote, stockholders did not approve the stockholder proposal relating to special shareholder meeting improvement:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

144,332,872   268,232,028   1,239,398   34,040,779

 

(g)

By the following vote, stockholders did not approve the stockholder proposal relating to an independent board chairman:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

94,067,610   318,684,398   1,052,290   34,040,779

 

Item 9.01

Financial Statements and Exhibits.

 

    

Description

3.1    Amended and Restated Certificate of Incorporation of Baxter International Inc. dated May 5, 2022
3.2    Amended and Restated Bylaws dated May 5, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 6, 2022

 

BAXTER INTERNATIONAL INC.
 

/s/ Ellen K. Bradford

By:   Ellen K. Bradford
  Senior Vice President and Corporate Secretary